Long-term community hospital experience with the internal defibrillator.
Seventy-seven patients with drug refractory ventricular tachycardia (57) and ventricular fibrillation (20) received the implantable defibrillator. There were 55 men and 22 women with a mean age of 63 +/- 10 years. The anatomical diagnoses were coronary artery disease in 61 patients, cardiomyopathy in 15 patients, and aortic stenosis in one patient. The mean ejection fraction was 32 +/- 12%. Concurrent surgery at defibrillator implantation was coronary bypass in eight patients and aortic valve replacement in one patient. There were no intraoperative mortalities. The mean ventricular fibrillation termination threshold was 13 +/- 6 joules. During a follow-up period of 16 +/- 10 months (range 2-40 months) four patients died: electrical mechanical dissociation (two patients), respiratory failure, and sepsis. Thirty-eight patients (51%) continued receiving antiarrhythmic drug therapy, with quinidine sulfate and procainamide being the most frequently utilized agents. Fifty-four patients (72%) have received a mean of 9 +/- 10 shocks (range 1-44). Implantable defibrillators are often needed in patients seen in large community hospitals. This technology can be administered successfully in this setting with complications and results comparable to those reported from university hospitals. Implantable defibrillators are effective in preventing arrhythmic death and can be used with low risk to the patients.
Porterfield
J G
JG
Methodist Hospital, Memphis, Tennessee.
Porterfield
L M
LM
Bray
L
L
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D004554:Electric Countershock / Q000295:instrumentation*; D005260:Female; D005500:Follow-Up Studies; D006764:Hospitals, Community; D006801:Humans; D008297:Male; D008875:Middle Aged; D019736:Prostheses and Implants; D013610:Tachycardia / Q000453:epidemiology / Q000628:therapy*; D013714:Tennessee / Q000453:epidemiology; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000453:epidemiology / Q000628:therapy*
D000889:Anti-Arrhythmia Agents